Characterization of novel monoclonal antibodies that target proteins differentially expressed in hepatocellular carcinoma : a proteomics approach
- Publisher: Bilkent University
Carcinogenesis. | Monoclonal antibodies. | Antibodies--genetics. | Liver cancer. | WI735 .O98 2011 | Carcinoma, Hepatocellular. | Antibodies, Monoclonal.
mesheuropmc: digestive system diseases
Ankara : The Department of Molecular Biology and Genetics and the Institute of Engineering and Science of Bilkent University, 2011.
Thesis (Ph. D.) -- Bilkent University, 2011.
Includes bibliographical references leaves 85-91.
Hepatocellular carcinoma (HCC) is the sixth common cancer in the world. Because of the late
diagnosis of the disease, survival rates are still poor in the HCC patients. Surveillance
strategies have to be developed in populations with high risk groups having premalignant
diseases for HCC, such as liver cirrhosis. The usage of serum and histology-based biomarkers
assists health professionals to evaluate the patients. Despite of the advances in diagnostic
methods, there is still a need to develop novel biomarkers for early detection of HCC.
Therefore, we aimed to develop new biomarkers with higher sensitivity and specificity for
HCC to improve the surveillance of the patients. Using an apoptotic HCC cell line, HUH7,
and SIP1 proteins, we generated novel monoclonal antibodies (mAbs). 6D5, 1C6 and 6E5
hybridoma clones were chosen for characterization studies because of their strong reactivity
in cell-ELISA assays. We found differential reactivity pattern for those novel mAbs in a panel
of human sections consisting of tumors, benign liver diseases, normal tissues and a variety of
cell lines. Using proteomics methods, we identified candidate target proteins for the 6D5
mAb. Better characterization of these target proteins will provide a better understanding of the
molecular pathways in the HCC and aid in the research for developing newer therapeutic
agents. In conclusion, our candidate biomarker mAbs can be used in the early diagnosis of
HCC as well as in drug development studies.